| Published Application/Species/Sample/Dilution | Reference |
|---|
- other; human; fig 3c, s8d
| Permanne B, Sand A, Ousson S, N xe9 ny M, Hantson J, Schubert R, et al. O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies. ACS Chem Neurosci. 2022;13:1296-1314 pubmed publisher |
- immunohistochemistry; mouse; 1:200; loading ...
| Choi Y, Dunn Meynell A, Marchese M, Blumberg B, Gaindh D, Dowling P, et al. Erythropoietin-derived peptide treatment reduced neurological deficit and neuropathological changes in a mouse model of tauopathy. Alzheimers Res Ther. 2021;13:32 pubmed publisher |
| Natarajan C, Cook C, Ramaswamy K, Krishnan B. Phospholipase D1 Attenuation Therapeutics Promotes Resilience against Synaptotoxicity in 12-Month-Old 3xTg-AD Mouse Model of Progressive Neurodegeneration. Int J Mol Sci. 2023;24: pubmed publisher |
| Shao E, Chang C, Li Z, Yu X, Ho K, Zhang M, et al. TAU ablation in excitatory neurons and postnatal TAU knockdown reduce epilepsy, SUDEP, and autism behaviors in a Dravet syndrome model. Sci Transl Med. 2022;14:eabm5527 pubmed publisher |
| Abdelhamid M, Zhou C, Ohno K, Kuhara T, Taslima F, Abdullah M, et al. Probiotic Bifidobacterium breve Prevents Memory Impairment Through the Reduction of Both Amyloid-β Production and Microglia Activation in APP Knock-In Mouse. J Alzheimers Dis. 2022;85:1555-1571 pubmed publisher |
| Montalbano M, McAllen S, Cascio F, Sengupta U, Garcia S, Bhatt N, et al. TDP-43 and Tau Oligomers in Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia. Neurobiol Dis. 2020;146:105130 pubmed publisher |
| Lo Cascio F, Garcia S, Montalbano M, Puangmalai N, McAllen S, Pace A, et al. Modulating disease-relevant tau oligomeric strains by small molecules. J Biol Chem. 2020;295:14807-14825 pubmed publisher |
| Puangmalai N, Bhatt N, Montalbano M, Sengupta U, Gaikwad S, Ventura F, et al. Internalization mechanisms of brain-derived tau oligomers from patients with Alzheimer's disease, progressive supranuclear palsy and dementia with Lewy bodies. Cell Death Dis. 2020;11:314 pubmed publisher |
| Sengupta U, Puangmalai N, Bhatt N, Garcia S, Zhao Y, Kayed R. Polymorphic α-Synuclein Strains Modified by Dopamine and Docosahexaenoic Acid Interact Differentially with Tau Protein. Mol Neurobiol. 2020;57:2741-2765 pubmed publisher |
| Lo Cascio F, Puangmalai N, Ellsworth A, Bucchieri F, Pace A, Palumbo Piccionello A, et al. Toxic Tau Oligomers Modulated by Novel Curcumin Derivatives. Sci Rep. 2019;9:19011 pubmed publisher |
| Franklin W, Krishnan B, Taglialatela G. Chronic synaptic insulin resistance after traumatic brain injury abolishes insulin protection from amyloid beta and tau oligomer-induced synaptic dysfunction. Sci Rep. 2019;9:8228 pubmed publisher |
| Guix F, Corbett G, Cha D, Mustapic M, Liu W, Mengel D, et al. Detection of Aggregation-Competent Tau in Neuron-Derived Extracellular Vesicles. Int J Mol Sci. 2018;19: pubmed publisher |
| Sengupta U, Portelius E, Hansson O, Farmer K, Castillo Carranza D, Woltjer R, et al. Tau oligomers in cerebrospinal fluid in Alzheimer's disease. Ann Clin Transl Neurol. 2017;4:226-235 pubmed publisher |
| Kotfis K, Zegan Barańska M, Szydłowski Ł, Zukowski M, Ely E. Methods of pain assessment in adult intensive care unit patients - Polish version of the CPOT (Critical Care Pain Observation Tool) and BPS (Behavioral Pain Scale). Anaesthesiol Intensive Ther. 2017;49:66-72 pubmed publisher |
| Kim H, Moon S, Kim S, Lee M, Suk M, Park D, et al. Chronological changes in the expression of phosphorylated tau and 5‑AMP‑activated protein kinase in the brain of senescence‑accelerated P8 mice. Mol Med Rep. 2017;15:3301-3309 pubmed publisher |
| Liechtenstein T, Perez Janices N, Blanco Luquin I, Goyvaerts C, Schwarze J, Dufait I, et al. Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy. Oncoimmunology. 2014;3:e945378 pubmed |
